Health Catalyst (HCAT) Financials

$3.74 -0.20 (-5.08%)

Closing price 04:00 PM Eastern

Extended Trading

$3.74 +0.00 (+0.13%)

As of 04:16 PM Eastern

Annual Income Statements for Health Catalyst

This table shows Health Catalyst's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Income / (Loss) Attributable to Common Shareholders	-70	-118	-137
Consolidated Net Income / (Loss)	-70	-118	-137
Net Income / (Loss) Continuing Operations	-70	-118	-137
Total Pre-Tax Income	-69	-118	-142
Total Operating Income	-70	-127	-140
Total Gross Profit	141	132	133
Total Revenue	307	296	276
Operating Revenue	307	296	276
Total Cost of Revenue	166	164	143
Operating Cost of Revenue	166	164	143
Total Operating Expenses	211	259	273
Selling, General & Admin Expense	57	77	62
Marketing Expense	54	67	88
Research & Development Expense	58	73	76
Depreciation Expense	41	42	48
Total Other Income / (Expense), net	0.64	9.11	-1.68
Interest & Investment Income	0.64	9.11	-1.68
Income Tax Expense	0.33	0.36	-4.28
Basic Earnings per Share	($1.15)	($2.09)	($2.56)
Weighted Average Basic Shares Outstanding	60.18M	56.42M	53.72M
Diluted Earnings per Share	($1.15)	($2.09)	($2.63)
Weighted Average Diluted Shares Outstanding	60.18M	56.42M	54.08M
Weighted Average Basic & Diluted Shares Outstanding	70.21M	58.56M	55.81M

This table shows Health Catalyst's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	-21	-15	-14	-21	-30	-22	-33	-33	-36	-46
Consolidated Net Income / (Loss)	-21	-15	-14	-21	-30	-22	-33	-33	-36	-46
Net Income / (Loss) Continuing Operations	-21	-15	-14	-21	-30	-22	-33	-33	-36	-46
Total Pre-Tax Income	-20	-15	-13	-20	-30	-22	-33	-33	-36	-46
Total Operating Income	-18	-14	-16	-23	-33	-25	-35	-35	-37	-46
Total Gross Profit	35	34	36	36	31	32	34	36	31	32
Total Revenue	80	76	76	75	75	74	73	74	69	68
Operating Revenue	80	76	76	75	75	74	73	74	69	68
Total Cost of Revenue	45	42	40	39	45	42	39	38	38	36
Operating Cost of Revenue	45	42	40	39	45	42	39	38	38	36
Total Operating Expenses	52	48	52	59	63	57	68	70	68	78
Selling, General & Admin Expense	16	12	14	15	15	14	24	24	16	19
Marketing Expense	11	11	13	19	17	15	16	19	20	25
Research & Development Expense	15	14	14	15	20	18	18	17	20	21
Depreciation Expense	10	9.98	11	11	10	10	11	11	12	12
Total Other Income / (Expense), net	-2.55	-1.51	2.36	2.34	2.62	2.61	2.09	1.79	1.02	0.14
Interest & Investment Income	-2.55	-1.51	2.36	2.34	2.62	2.61	2.09	1.79	-	-
Income Tax Expense	0.63	-0.48	0.07	0.11	0.14	0.06	0.09	0.07	0.06	0.16
Basic Earnings per Share	($0.33)	($0.24)	($0.23)	($0.35)	($0.52)	($0.39)	($0.58)	($0.60)	($0.68)	($0.84)
Weighted Average Basic Shares Outstanding	60.18M	60.44M	59.30M	58.59M	56.42M	56.71M	55.98M	55.48M	53.72M	54.30M
Diluted Earnings per Share	($0.33)	($0.24)	($0.23)	($0.35)	($0.52)	($0.39)	($0.58)	($0.60)	($0.63)	($0.84)
Weighted Average Diluted Shares Outstanding	60.18M	60.44M	59.30M	58.59M	56.42M	56.71M	55.98M	55.48M	54.08M	54.30M
Weighted Average Basic & Diluted Shares Outstanding	70.21M	60.85M	60.47M	59.03M	58.56M	57.55M	56.96M	56.26M	55.81M	54.75M

This table details how cash moves in and out of Health Catalyst's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Net Change in Cash & Equivalents	143	-10	-77
Net Cash From Operating Activities	15	-33	-35
Net Cash From Continuing Operating Activities	15	-33	-35
Net Income / (Loss) Continuing Operations	-70	-118	-137
Consolidated Net Income / (Loss)	-70	-118	-137
Depreciation Expense	41	42	48
Amortization Expense	-1.50	-8.21	-0.74
Non-Cash Adjustments To Reconcile Net Income	46	65	78
Changes in Operating Assets and Liabilities, net	-2.08	-14	-23
Net Cash From Investing Activities	-23	20	-39
Net Cash From Continuing Investing Activities	-23	20	-39
Purchase of Property, Plant & Equipment	-1.62	-1.24	-2.17
Acquisitions	-81	-13	-30
Purchase of Investments	-168	-291	-309
Sale of Property, Plant & Equipment	0.01	0.03	0.03
Sale and/or Maturity of Investments	242	337	315
Other Investing Activities, net	-14	-12	-13
Net Cash From Financing Activities	152	2.73	-2.61
Net Cash From Continuing Financing Activities	152	2.73	-2.61
Repayment of Debt	-3.11	0.00	0.00
Repurchase of Common Equity	0.00	-1.81	-8.39
Issuance of Debt	152	0.00	0.00
Issuance of Common Equity	2.41	3.59	3.15
Other Financing Activities, net	0.17	0.95	2.63
Effect of Exchange Rate Changes	-0.03	0.02	-0.01
Cash Interest Paid	10	5.75	5.75
Cash Income Taxes Paid	0.27	0.27	0.30

This table details how cash moves in and out of Health Catalyst's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-79	126	0.53	95	11	-21	-18	17	-7.91	-53
Net Cash From Operating Activities	-3.53	6.21	1.61	10	-19	3.12	-12	-5.58	-15	-12
Net Cash From Continuing Operating Activities	-3.53	6.21	1.61	10	-19	3.12	-12	-5.58	-15	-12
Net Income / (Loss) Continuing Operations	-21	-15	-14	-21	-30	-22	-33	-33	-36	-46
Consolidated Net Income / (Loss)	-21	-15	-14	-21	-30	-22	-33	-33	-36	-46
Depreciation Expense	10	9.98	11	11	10	10	11	11	12	12
Amortization Expense	0.32	0.57	-0.80	-1.59	-2.53	-2.44	-1.64	-1.60	-1.25	-0.64
Non-Cash Adjustments To Reconcile Net Income	9.29	10	11	16	15	15	18	16	16	23
Changes in Operating Assets and Liabilities, net	-2.73	0.33	-5.38	5.69	-12	2.33	-6.15	2.06	-5.83	-1.36
Net Cash From Investing Activities	-113	7.65	-1.78	84	30	-25	-7.42	23	6.26	-33
Net Cash From Continuing Investing Activities	-113	7.65	-1.78	84	30	-25	-7.42	23	6.26	-33
Purchase of Property, Plant & Equipment	-0.41	-0.71	-0.29	-0.21	-0.26	-0.15	-0.41	-0.43	-0.42	-1.19
Acquisitions	-25	-36	-19	-0.08	-12	-0.02	-0.87	-0.10	-0.94	-0.02
Purchase of Investments	-118	-	-	-50	-36	-89	-84	-81	-34	-114
Sale of Property, Plant & Equipment	0.00	0.00	0.00	0.00	0.01	0.01	0.01	0.01	0.01	0.01
Sale and/or Maturity of Investments	36	48	21	137	81	68	82	107	45	85
Other Investing Activities, net	-4.42	-3.57	-3.76	-2.53	-2.63	-2.94	-3.53	-2.86	-2.96	-3.00
Net Cash From Financing Activities	38	112	0.70	0.86	0.40	1.04	1.20	0.09	0.64	-7.54
Net Cash From Continuing Financing Activities	38	112	0.70	0.86	0.40	1.04	1.20	0.09	0.64	-7.54
Repayment of Debt	0.54	-	-	-	-	-	-	-	-	-
Issuance of Debt	37	-	-	-	-	-	-	-	-	-
Issuance of Common Equity	0.35	0.63	0.59	0.84	0.38	1.00	1.03	1.17	0.60	1.03
Effect of Exchange Rate Changes	-0.10	0.08	-0.00	-0.02	0.03	-0.02	-0.00	0.01	0.02	-0.01

This table presents Health Catalyst's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Total Assets	859	702	752
Total Current Assets	466	393	428
Cash & Equivalents	250	106	116
Short-Term Investments	142	211	247
Accounts Receivable	57	60	48
Prepaid Expenses	16	15	16
Plant, Property, & Equipment, net	29	26	26
Total Noncurrent Assets	364	283	299
Goodwill	260	191	186
Intangible Assets	86	73	92
Other Noncurrent Operating Assets	18	19	20
Total Liabilities & Shareholders' Equity	859	702	752
Total Liabilities	494	335	327
Total Current Liabilities	326	89	83
Short-Term Debt	231	0.00	-
Accounts Payable	11	6.64	4.42
Accrued Expenses	26	23	20
Current Deferred Revenue	53	56	55
Other Current Liabilities	3.61	3.36	3.43
Total Noncurrent Liabilities	168	246	245
Long-Term Debt	151	228	227
Noncurrent Deferred Revenue	0.25	0.08	0.11
Other Noncurrent Operating Liabilities	16	18	18
Commitments & Contingencies	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	365	367	425
Total Preferred & Common Equity	365	367	425
Preferred Stock	0.00	0.00	0.00
Total Common Equity	365	367	425
Common Stock	1,553	1,484	1,425
Retained Earnings	-1,187	-1,117	-999
Accumulated Other Comprehensive Income / (Loss)	-0.84	0.03	-0.65

This table presents Health Catalyst's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022
Period end date	9/30/2024	6/30/2024	3/31/2024	9/30/2023	6/30/2023	3/31/2023	9/30/2022
Total Assets	813	692	695	713	723	752	776
Total Current Assets	457	376	397	408	411	435	443
Cash & Equivalents	328	202	201	95	116	133	124
Short-Term Investments	59	106	126	253	228	223	256
Accounts Receivable	52	55	54	46	52	62	50
Prepaid Expenses	19	13	15	15	15	16	14
Plant, Property, & Equipment, net	28	26	25	26	26	26	25
Total Noncurrent Assets	328	290	273	278	286	291	308
Goodwill	234	206	191	186	186	186	186
Intangible Assets	76	67	66	72	79	84	101
Other Noncurrent Operating Assets	17	17	16	20	21	21	21
Total Liabilities & Shareholders' Equity	813	692	695	713	723	752	776
Total Liabilities	458	335	338	331	333	347	336
Total Current Liabilities	324	318	92	84	87	102	91
Short-Term Debt	230	0.89	3.35	-	-	-	0.00
Accounts Payable	14	11	5.70	6.33	7.97	9.24	6.82
Accrued Expenses	24	18	20	21	16	24	24
Current Deferred Revenue	52	56	64	53	60	66	56
Other Current Liabilities	3.33	232	-	3.40	3.47	3.39	3.46
Total Noncurrent Liabilities	134	17	246	246	246	245	245
Long-Term Debt	115	0.00	228	228	227	227	226
Noncurrent Deferred Revenue	0.26	0.05	0.08	0.31	0.09	0.19	0.32
Other Noncurrent Operating Liabilities	19	17	0.09	18	19	18	19
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	355	357	357	382	390	405	440
Total Preferred & Common Equity	355	357	357	382	390	405	440
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	355	357	357	382	390	405	440
Common Stock	1,521	1,508	1,495	1,469	1,455	1,438	1,404
Retained Earnings	-1,166	-1,151	-1,138	-1,087	-1,065	-1,032	-963
Accumulated Other Comprehensive Income / (Loss)	-0.11	-0.16	-0.12	-0.17	-0.20	-0.30	-0.88

This table displays calculated financial ratios and metrics derived from Health Catalyst's official financial filings.

Metric	2024	2023	2022
Period end date	12/31/2024	12/31/2023	12/31/2022
Growth Metrics	-	-	-
Revenue Growth	3.60%	7.13%	14.18%
EBITDA Growth	67.83%	-0.47%	0.57%
EBIT Growth	44.99%	9.36%	2.54%
NOPAT Growth	44.99%	9.36%	2.54%
Net Income Growth	41.17%	14.01%	10.32%
EPS Growth	44.98%	20.53%	18.58%
Operating Cash Flow Growth	144.01%	6.21%	-52.53%
Free Cash Flow Firm Growth	-63.06%	36.79%	29.29%
Invested Capital Growth	28.26%	-3.76%	9.67%
Revenue Q/Q Growth	1.50%	2.04%	1.64%
EBITDA Q/Q Growth	37.72%	1.41%	4.03%
EBIT Q/Q Growth	17.96%	3.03%	5.42%
NOPAT Q/Q Growth	17.96%	3.03%	5.42%
Net Income Q/Q Growth	12.18%	4.43%	8.77%
EPS Q/Q Growth	14.18%	5.00%	11.15%
Operating Cash Flow Q/Q Growth	1,624.50%	-14.62%	-16.70%
Free Cash Flow Firm Q/Q Growth	-15.61%	-14.75%	57.88%
Invested Capital Q/Q Growth	13.67%	5.67%	0.72%
Profitability Metrics	-	-	-
Gross Margin	45.92%	44.55%	48.21%
EBITDA Margin	-9.74%	-31.39%	-33.47%
Operating Margin	-22.77%	-42.88%	-50.68%
EBIT Margin	-22.77%	-42.88%	-50.68%
Profit (Net Income) Margin	-22.67%	-39.92%	-49.74%
Tax Burden Percent	100.48%	100.30%	96.98%
Interest Burden Percent	99.09%	92.82%	101.20%
Effective Tax Rate	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-15.44%	-31.43%	-35.59%
ROIC Less NNEP Spread (ROIC-NNEP)	26.11%	-5.56%	-15.72%
Return on Net Nonoperating Assets (RNNOA)	-3.54%	1.59%	6.58%
Return on Equity (ROE)	-18.99%	-29.84%	-29.02%
Cash Return on Invested Capital (CROIC)	-40.20%	-27.60%	-44.82%
Operating Return on Assets (OROA)	-8.95%	-17.45%	-17.67%
Return on Assets (ROA)	-8.91%	-16.25%	-17.34%
Return on Common Equity (ROCE)	-18.99%	-29.84%	-29.02%
Return on Equity Simple (ROE_SIMPLE)	-19.03%	-32.20%	-32.33%
Net Operating Profit after Tax (NOPAT)	-49	-89	-98
NOPAT Margin	-15.94%	-30.02%	-35.48%
Net Nonoperating Expense Percent (NNEP)	-41.55%	-25.87%	-19.88%
Return On Investment Capital (ROIC_SIMPLE)	-6.54%	-14.93%	-15.04%
Cost of Revenue to Revenue	54.08%	55.45%	51.79%
SG&A Expenses to Revenue	18.53%	25.87%	22.34%
R&D to Revenue	18.90%	24.54%	27.40%
Operating Expenses to Revenue	68.69%	87.43%	98.90%
Earnings before Interest and Taxes (EBIT)	-70	-127	-140
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-30	-93	-92
Valuation Ratios	-	-	-
Price to Book Value (P/BV)	1.18	1.45	1.37
Price to Tangible Book Value (P/TBV)	22.18	5.18	3.96
Price to Revenue (P/Rev)	1.40	1.80	2.11
Price to Earnings (P/E)	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.18	1.60	1.55
Enterprise Value to Revenue (EV/Rev)	1.37	1.50	1.61
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	28.89	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00
Leverage & Solvency	-	-	-
Debt to Equity	1.05	0.62	0.53
Long-Term Debt to Equity	0.41	0.62	0.53
Financial Leverage	-0.14	-0.29	-0.42
Leverage Ratio	2.13	1.84	1.67
Compound Leverage Factor	2.11	1.70	1.69
Debt to Total Capital	51.15%	38.33%	34.77%
Short-Term Debt to Total Capital	30.92%	0.00%	0.00%
Long-Term Debt to Total Capital	20.22%	38.33%	34.77%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%
Common Equity to Total Capital	48.85%	61.67%	65.23%
Debt to EBITDA	-12.80	-2.46	-2.45
Net Debt to EBITDA	0.32	0.97	1.48
Long-Term Debt to EBITDA	-5.06	-2.46	-2.45
Debt to NOPAT	-7.83	-2.57	-2.31
Net Debt to NOPAT	0.20	1.01	1.40
Long-Term Debt to NOPAT	-3.09	-2.57	-2.31
Altman Z-Score	-1.13	-0.93	-0.49
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-
Current Ratio	1.43	4.42	5.18
Quick Ratio	1.38	4.25	4.99
Cash Flow Metrics	-	-	-
Free Cash Flow to Firm (FCFF)	-127	-78	-123
Operating Cash Flow to CapEx	908.23%	-2,745.23%	-1,649.67%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00
Efficiency Ratios	-	-	-
Asset Turnover	0.39	0.41	0.35
Accounts Receivable Turnover	5.22	5.47	5.71
Inventory Turnover	0.00	0.00	0.00
Fixed Asset Turnover	11.13	11.46	11.22
Accounts Payable Turnover	18.35	29.66	31.38
Days Sales Outstanding (DSO)	69.93	66.76	63.93
Days Inventory Outstanding (DIO)	0.00	0.00	0.00
Days Payable Outstanding (DPO)	19.89	12.31	11.63
Cash Conversion Cycle (CCC)	50.03	54.46	52.30
Capital & Investment Metrics	-	-	-
Invested Capital	356	277	288
Invested Capital Turnover	0.97	1.05	1.00
Increase / (Decrease) in Invested Capital	78	-11	25
Enterprise Value (EV)	421	443	445
Market Capitalization	430	533	582
Book Value per Share	$6.00	$6.38	$7.76
Tangible Book Value per Share	$0.32	$1.79	$2.68
Total Capital	748	595	652
Total Debt	382	228	227
Total Long-Term Debt	151	228	227
Net Debt	-9.64	-90	-137
Capital Expenditures (CapEx)	1.60	1.21	2.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-13	-18
Debt-free Net Working Capital (DFNWC)	371	304	345
Net Working Capital (NWC)	140	304	345
Net Nonoperating Expense (NNE)	21	29	39
Net Nonoperating Obligations (NNO)	-9.64	-90	-137
Total Depreciation and Amortization (D&A)	40	34	48
Debt-free, Cash-free Net Working Capital to Revenue	-6.86%	-4.52%	-6.59%
Debt-free Net Working Capital to Revenue	121.01%	102.85%	125.00%
Net Working Capital to Revenue	45.60%	102.85%	125.00%
Earnings Adjustments	-	-	-
Adjusted Basic Earnings per Share	($1.15)	($2.09)	($2.56)
Adjusted Weighted Average Basic Shares Outstanding	60.18M	56.42M	53.72M
Adjusted Diluted Earnings per Share	($1.15)	($2.09)	($2.63)
Adjusted Weighted Average Diluted Shares Outstanding	60.18M	56.42M	54.08M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	70.21M	58.56M	55.81M
Normalized Net Operating Profit after Tax (NOPAT)	-49	-89	-98
Normalized NOPAT Margin	-15.94%	-30.02%	-35.48%
Pre Tax Income Margin	-22.56%	-39.80%	-51.29%
Debt Service Ratios	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00
Payout Ratios	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	-1.53%	-6.11%

This table displays calculated financial ratios and metrics derived from Health Catalyst's official financial filings.

Metric	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	6.02%	3.50%	3.67%	1.16%	8.56%	7.93%	3.65%	8.49%	6.87%	10.72%
EBITDA Growth	72.35%	81.37%	76.68%	45.64%	5.04%	50.48%	-26.37%	-114.00%	12.84%	-19.40%
EBIT Growth	46.62%	44.32%	54.34%	34.66%	10.78%	46.24%	-4.30%	-43.40%	17.92%	-8.22%
NOPAT Growth	46.62%	44.32%	54.34%	34.66%	10.78%	46.24%	-4.30%	-43.40%	17.92%	-8.22%
Net Income Growth	31.80%	33.16%	58.56%	37.97%	15.29%	51.83%	2.44%	-47.79%	26.96%	-14.30%
EPS Growth	36.54%	38.46%	60.34%	41.67%	17.46%	53.57%	6.45%	-11.11%	34.38%	-2.44%
Operating Cash Flow Growth	81.48%	99.29%	113.93%	283.98%	-28.47%	125.89%	-20.86%	-581.87%	-51.62%	-124.46%
Free Cash Flow Firm Growth	-646.75%	-1,036.28%	4,884.64%	-10.72%	76.27%	102.90%	98.52%	93.85%	51.45%	-414.54%
Invested Capital Growth	28.26%	19.23%	-81.84%	1.16%	-3.76%	-8.26%	-6.75%	-2.53%	9.67%	195.97%
Revenue Q/Q Growth	4.26%	0.59%	1.58%	-0.48%	1.78%	0.76%	-0.89%	6.80%	1.18%	-3.23%
EBITDA Q/Q Growth	-120.47%	47.32%	57.09%	44.52%	-48.59%	34.07%	-0.02%	3.08%	22.52%	-68.24%
EBIT Q/Q Growth	-27.86%	13.41%	30.71%	30.42%	-33.38%	29.00%	0.85%	4.98%	19.63%	-37.75%
NOPAT Q/Q Growth	-27.86%	13.41%	30.71%	30.42%	-33.38%	29.00%	0.85%	4.98%	19.63%	-37.75%
Net Income Q/Q Growth	-40.38%	-8.95%	34.35%	32.08%	-37.58%	32.44%	1.74%	7.24%	21.76%	-36.82%
EPS Q/Q Growth	-37.50%	-4.35%	34.29%	32.69%	-33.33%	32.76%	3.33%	4.76%	25.00%	-35.48%
Operating Cash Flow Q/Q Growth	-156.81%	285.11%	-84.30%	153.92%	-711.27%	126.91%	-107.42%	62.35%	-23.19%	-25.64%
Free Cash Flow Firm Q/Q Growth	-50.88%	-128.24%	1,210.44%	-57.82%	-289.17%	244.32%	74.30%	66.18%	76.90%	26.35%
Invested Capital Q/Q Growth	13.67%	530.17%	-82.16%	0.39%	5.67%	-4.01%	-0.66%	-4.49%	0.72%	-2.43%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	43.58%	44.58%	47.22%	48.45%	40.63%	43.36%	46.13%	48.15%	44.90%	46.84%
EBITDA Margin	-8.69%	-4.11%	-7.84%	-18.57%	-33.30%	-22.81%	-34.87%	-34.55%	-38.07%	-49.72%
Operating Margin	-21.98%	-17.93%	-20.83%	-30.53%	-43.66%	-33.32%	-47.28%	-47.27%	-53.13%	-66.89%
EBIT Margin	-21.98%	-17.93%	-20.83%	-30.53%	-43.66%	-33.32%	-47.28%	-47.27%	-53.13%	-66.89%
Profit (Net Income) Margin	-25.97%	-19.29%	-17.81%	-27.55%	-40.37%	-29.86%	-44.55%	-44.93%	-51.74%	-66.91%
Tax Burden Percent	103.12%	96.88%	100.52%	100.55%	100.47%	100.27%	100.26%	100.21%	100.17%	100.34%
Interest Burden Percent	114.56%	111.06%	85.06%	89.75%	92.02%	89.39%	93.96%	94.86%	97.22%	99.69%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	-14.91%	-13.18%	-27.04%	-22.92%	-32.00%	-24.67%	-33.26%	-33.48%	-37.31%	-66.52%
ROIC Less NNEP Spread (ROIC-NNEP)	2.05%	-6.84%	-25.88%	-18.50%	-25.51%	-21.15%	-27.53%	-28.16%	-32.24%	-62.00%
Return on Net Nonoperating Assets (RNNOA)	-0.28%	1.50%	14.69%	5.07%	7.30%	7.05%	9.38%	10.44%	13.49%	38.02%
Return on Equity (ROE)	-15.19%	-11.68%	-12.35%	-17.85%	-24.70%	-17.62%	-23.89%	-23.04%	-23.82%	-28.51%
Cash Return on Invested Capital (CROIC)	-40.20%	-38.26%	96.91%	-30.19%	-27.60%	-24.80%	-30.58%	-35.26%	-44.82%	-153.15%
Operating Return on Assets (OROA)	-8.64%	-7.10%	-8.82%	-12.52%	-17.77%	-12.98%	-17.54%	-16.90%	-18.53%	-22.42%
Return on Assets (ROA)	-10.20%	-7.64%	-7.54%	-11.30%	-16.43%	-11.63%	-16.53%	-16.07%	-18.04%	-22.43%
Return on Common Equity (ROCE)	-15.19%	-11.68%	-12.35%	-17.85%	-24.70%	-17.62%	-23.89%	-23.04%	-23.82%	-28.51%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-22.29%	-24.21%	-29.55%	0.00%	-32.33%	-37.79%	-36.56%	0.00%	-34.23%
Net Operating Profit after Tax (NOPAT)	-12	-9.58	-11	-16	-23	-17	-24	-24	-26	-32
NOPAT Margin	-15.39%	-12.55%	-14.58%	-21.37%	-30.57%	-23.32%	-33.10%	-33.09%	-37.19%	-46.82%
Net Nonoperating Expense Percent (NNEP)	-16.96%	-6.34%	-1.16%	-4.42%	-6.50%	-3.52%	-5.73%	-5.32%	-5.08%	-4.53%
Return On Investment Capital (ROIC_SIMPLE)	-1.64%	-	-	-	-3.86%	-	-	-	-3.95%	-
Cost of Revenue to Revenue	56.42%	55.42%	52.78%	51.55%	59.37%	56.64%	53.87%	51.85%	55.10%	53.16%
SG&A Expenses to Revenue	19.70%	15.99%	18.92%	19.49%	20.55%	18.47%	32.33%	32.26%	23.35%	28.08%
R&D to Revenue	18.85%	18.59%	18.29%	19.90%	27.02%	23.95%	24.03%	23.13%	28.36%	30.39%
Operating Expenses to Revenue	65.56%	62.51%	68.05%	78.98%	84.30%	76.68%	93.42%	95.41%	98.03%	113.72%
Earnings before Interest and Taxes (EBIT)	-18	-14	-16	-23	-33	-25	-35	-35	-37	-46
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-6.91	-3.14	-5.95	-14	-25	-17	-26	-26	-26	-34
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.18	1.39	1.06	1.21	1.45	1.51	1.80	1.61	1.37	1.21
Price to Tangible Book Value (P/TBV)	22.18	11.14	4.49	4.32	5.18	4.63	5.63	4.83	3.96	3.46
Price to Revenue (P/Rev)	1.40	1.63	1.26	1.46	1.80	1.99	2.47	2.31	2.11	1.95
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.18	1.44	1.41	1.27	1.60	1.74	2.15	1.89	1.55	1.32
Enterprise Value to Revenue (EV/Rev)	1.37	1.49	0.23	1.19	1.50	1.57	2.06	1.85	1.61	1.39
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	28.89	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.45	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.05	0.97	0.00	0.70	0.62	0.60	0.58	0.56	0.53	0.51
Long-Term Debt to Equity	0.41	0.32	0.00	0.69	0.62	0.60	0.58	0.56	0.53	0.51
Financial Leverage	-0.14	-0.22	-0.57	-0.27	-0.29	-0.33	-0.34	-0.37	-0.42	-0.61
Leverage Ratio	2.13	2.07	1.89	1.90	1.84	1.81	1.79	1.78	1.67	1.64
Compound Leverage Factor	2.44	2.30	1.61	1.70	1.69	1.62	1.68	1.69	1.63	1.63
Debt to Total Capital	51.15%	49.29%	0.25%	41.06%	38.33%	37.32%	36.83%	35.90%	34.77%	33.95%
Short-Term Debt to Total Capital	30.92%	32.91%	0.25%	0.55%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	20.22%	16.37%	0.00%	40.51%	38.33%	37.32%	36.83%	35.90%	34.77%	33.95%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	48.85%	50.71%	99.75%	58.94%	61.67%	62.68%	63.17%	64.10%	65.23%	66.05%
Debt to EBITDA	-12.80	-7.19	-0.01	-3.06	-2.46	-2.42	-2.04	-2.14	-2.45	-2.35
Net Debt to EBITDA	0.32	0.88	4.98	0.97	0.97	1.27	1.05	1.23	1.48	1.60
Long-Term Debt to EBITDA	-5.06	-2.39	0.00	-3.02	-2.46	-2.42	-2.04	-2.14	-2.45	-2.35
Debt to NOPAT	-7.83	-5.79	-0.01	-3.10	-2.57	-2.49	-2.14	-2.15	-2.31	-2.18
Net Debt to NOPAT	0.20	0.71	4.57	0.98	1.01	1.31	1.10	1.23	1.40	1.49
Long-Term Debt to NOPAT	-3.09	-1.92	0.00	-3.06	-2.57	-2.49	-2.14	-2.15	-2.31	-2.18
Altman Z-Score	-0.93	-0.85	-1.20	-0.68	-0.49	-0.25	-0.02	-0.04	-0.04	-0.09
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.43	1.41	1.18	4.31	4.42	4.85	4.74	4.24	5.18	4.87
Quick Ratio	1.38	1.36	1.14	4.14	4.25	4.67	4.57	4.09	4.99	4.72
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-91	-60	213	-19	-12	6.41	-4.44	-17	-51	-221
Operating Cash Flow to CapEx	-860.24%	884.33%	563.64%	5,007.80%	-7,771.84%	2,241.01%	-2,879.10%	-1,331.74%	-3,650.49%	-1,016.13%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.39	0.40	0.42	0.41	0.41	0.39	0.37	0.36	0.35	0.34
Accounts Receivable Turnover	5.22	6.18	5.58	5.13	5.47	6.07	5.68	5.40	5.71	5.59
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	11.13	11.19	11.59	11.61	11.46	11.34	10.81	10.99	11.22	11.81
Accounts Payable Turnover	18.35	16.06	17.76	22.00	29.66	23.99	22.27	19.51	31.38	23.96
Days Sales Outstanding (DSO)	69.93	59.05	65.37	71.17	66.76	60.18	64.21	67.62	63.93	65.28
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	19.89	22.73	20.55	16.59	12.31	15.22	16.39	18.71	11.63	15.23
Cash Conversion Cycle (CCC)	50.03	36.32	44.82	54.57	54.46	44.96	47.82	48.91	52.30	50.05
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	356	313	50	278	277	262	273	275	288	286
Invested Capital Turnover	0.97	1.05	1.85	1.07	1.05	1.06	1.00	1.01	1.00	1.42
Increase / (Decrease) in Invested Capital	78	50	-224	3.18	-11	-24	-20	-7.15	25	189
Enterprise Value (EV)	421	450	70	354	443	456	587	521	445	377
Market Capitalization	430	492	377	433	533	576	703	651	582	531
Book Value per Share	$6.00	$5.87	$6.05	$6.10	$6.38	$6.71	$6.93	$7.26	$7.76	$8.04
Tangible Book Value per Share	$0.32	$0.73	$1.42	$1.71	$1.79	$2.18	$2.22	$2.41	$2.68	$2.80
Total Capital	748	700	358	606	595	610	617	632	652	666
Total Debt	382	345	0.89	249	228	228	227	227	227	226
Total Long-Term Debt	151	115	0.00	246	228	228	227	227	227	226
Net Debt	-9.64	-42	-307	-79	-90	-120	-117	-130	-137	-154
Capital Expenditures (CapEx)	0.41	0.70	0.29	0.21	0.25	0.14	0.40	0.42	0.41	1.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-21	-23	-249	-20	-13	-23	-20	-25	-18	-28
Debt-free Net Working Capital (DFNWC)	371	364	59	308	304	324	324	332	345	352
Net Working Capital (NWC)	140	134	58	305	304	324	324	332	345	352
Net Nonoperating Expense (NNE)	8.42	5.15	2.45	4.62	7.36	4.83	8.38	8.75	10	14
Net Nonoperating Obligations (NNO)	-9.64	-42	-307	-79	-90	-120	-117	-130	-137	-154
Total Depreciation and Amortization (D&A)	11	11	9.85	8.94	7.78	7.75	9.09	9.39	10	12
Debt-free, Cash-free Net Working Capital to Revenue	-6.86%	-7.68%	-83.25%	-6.57%	-4.52%	-8.10%	-6.90%	-8.83%	-6.59%	-10.21%
Debt-free Net Working Capital to Revenue	121.01%	120.52%	19.68%	103.87%	102.85%	111.79%	113.91%	117.73%	125.00%	129.65%
Net Working Capital to Revenue	45.60%	44.24%	19.38%	102.74%	102.85%	111.79%	113.91%	117.73%	125.00%	129.65%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($0.33)	($0.24)	($0.23)	($0.35)	($0.52)	($0.39)	($0.58)	($0.60)	($0.68)	($0.84)
Adjusted Weighted Average Basic Shares Outstanding	60.18M	60.44M	59.30M	58.59M	56.42M	56.71M	55.98M	55.48M	53.72M	54.30M
Adjusted Diluted Earnings per Share	($0.33)	($0.24)	($0.23)	($0.35)	($0.52)	($0.39)	($0.58)	($0.60)	($0.63)	($0.84)
Adjusted Weighted Average Diluted Shares Outstanding	60.18M	60.44M	59.30M	58.59M	56.42M	56.71M	55.98M	55.48M	54.08M	54.30M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	70.21M	60.85M	60.47M	59.03M	58.56M	57.55M	56.96M	56.26M	55.81M	54.75M
Normalized Net Operating Profit after Tax (NOPAT)	-12	-9.58	-11	-16	-23	-17	-24	-24	-26	-32
Normalized NOPAT Margin	-15.39%	-12.55%	-14.58%	-21.37%	-30.57%	-23.32%	-33.10%	-33.09%	-37.19%	-46.82%
Pre Tax Income Margin	-25.18%	-19.91%	-17.71%	-27.40%	-40.18%	-29.78%	-44.43%	-44.84%	-51.65%	-66.68%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	-1.53%	-1.46%	-6.92%	-6.89%	-6.11%	-5.57%

Frequently Asked Questions About Health Catalyst's Financials

When does Health Catalyst's financial year end?

According to the most recent income statement we have on file, Health Catalyst's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Health Catalyst's net income changed over the last 2 years?

Health Catalyst's net income appears to be on a downward trend, with a most recent value of -$69.50 million in 2024, falling from -$137.40 million in 2022. The previous period was -$118.15 million in 2023. See where experts think Health Catalyst is headed by visiting Health Catalyst's forecast page.

What is Health Catalyst's operating income?

Health Catalyst's total operating income in 2024 was -$69.81 million, based on the following breakdown:

Total Gross Profit: $140.78 million
Total Operating Expenses: $210.59 million

How has Health Catalyst revenue changed over the last 2 years?

Over the last 2 years, Health Catalyst's total revenue changed from $276.24 million in 2022 to $306.58 million in 2024, a change of 11.0%.

How much debt does Health Catalyst have?

Health Catalyst's total liabilities were at $493.72 million at the end of 2024, a 47.4% increase from 2023, and a 50.9% increase since 2022.

How much cash does Health Catalyst have?

In the past 2 years, Health Catalyst's cash and equivalents has ranged from $106.28 million in 2023 to $249.65 million in 2024, and is currently $249.65 million as of their latest financial filing in 2024.

How has Health Catalyst's book value per share changed over the last 2 years?

Over the last 2 years, Health Catalyst's book value per share changed from 7.76 in 2022 to 6.00 in 2024, a change of -22.7%.

Related Companies

This page (NASDAQ:HCAT) was last updated on 5/21/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Health Catalyst (HCAT) Financials

Frequently Asked Questions About Health Catalyst's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Health Catalyst (HCAT) Financials

Annual Income Statements for Health Catalyst

Quarterly Income Statements for Health Catalyst

Annual Cash Flow Statements for Health Catalyst

Quarterly Cash Flow Statements for Health Catalyst

Annual Balance Sheets for Health Catalyst

Quarterly Balance Sheets for Health Catalyst

Annual Metrics And Ratios for Health Catalyst

Quarterly Metrics And Ratios for Health Catalyst

Frequently Asked Questions About Health Catalyst's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools